Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
life sciences
national blog main
national top stories
roche
5
×
boston blog main
boston top stories
san francisco top stories
boston
clinical trials
deals
europe top stories
fda
genentech
san francisco blog main
avapritinib
blueprint medicines
cancer
drug prices
eli lilly
europe blog main
gene therapy
indiana blog main
indiana top stories
investing
medullary thyroid cancer
national
new york top stories
non-small cell lung cancer
novartis
pralsetinib
sarepta therapeutics
selpercatinib
thyroid cancer
acute myeloid leukemia
american society of clinical oncology
applied therapeutics
billy dunn
biogen
biopharma
What
fda
5
×
approval
drug
roche
therapy
blueprint
cancer
medicine
medicines
ret
address
ahead
approved
approves
asco
atrophy
betting
billion
bio
biopharma
branded
candidate
carries
certain
choices
commissioner
consumers
costly
counterweight
currently
daily
deal
designed
drugs
duchenne
elevatebio
evrysdi
friday
gene
generic
Language
unset
Current search:
roche
×
fda
×
biotech
×
@xconomy.com
4 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More